FDA Approves Simple Blood Test to Help Spot Alzheimer's Earlier
A simple blood draw could replace painful spinal taps for Alzheimer's testing.
Getting tested for Alzheimer's disease has often meant a painful spinal tap or an expensive brain scan. That may soon change. The FDA just approved a blood test called PrecivityAD2 that can help doctors identify signs of Alzheimer's with a simple blood draw. It was developed by a company connected to Washington University in St. Louis and is over 90% accurate in spotting the brain changes linked to the disease.
Why does this matter to you? Because catching Alzheimer's early makes a real difference. New treatments that slow the disease's progression are now available, and they work best when started as soon as possible. With a simple blood test, more people with memory concerns could get diagnosed earlier — and begin treatment while it can still help. The test also gives families answers much faster and with less stress than the older, more painful procedures.
There are a couple of things to know. The test doesn't diagnose Alzheimer's on its own; doctors use it along with your medical history and other exams to make a full picture. And although FDA clearance makes it more likely that insurance will cover it, it's not guaranteed yet for every plan. Still, this is a big step toward making Alzheimer's testing as routine as a cholesterol check — which could change millions of lives.
- The blood test is as accurate as spinal taps and brain scans, but far less painful and easier to get.
- Early detection lets patients start new Alzheimer's slowing drugs sooner, when they work best.
- FDA clearance makes insurance coverage more likely, so the test will be more affordable and accessible.
Why It Matters
Millions of families could get faster, less painful Alzheimer's answers and earlier treatment when it helps most.